Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 5, 2019

View Archived Issues

Dopamine goes from pleasure to repair molecule

Broad strategy for HIV bnAbs

Gene therapy can treat, prevent heart failure

iRhom2 is fibrosis friend, not foe

FDA approves Talicia for treatment of H. pylori in adults

Harbour BioMed initiates first-in-human study of HBM-4003

Positive interim safety and efficacy data presented for OTS Allocetra

Development of novel PRKACA inhibitors for the treatment of fibrolamellar carcinoma

KYM-003, potent and selective STAT3 degrader with strong antitumor activity in vivo

Preclinical data for SNSP-113 support its development as new approach to treat mucus stasis in CF

Novartis presents phase II data for QBW-276

VRN-071961: a potent EGFR kinase inhibitor active in Ex20Ins EGFR mutation-driven NSCLC

Promising preclinical results presented for DTX-701, a gene therapy for Wilson disease

AstraZeneca initiates phase I/IIa study of AZD-7648 alone and in combination for advanced cancers

Clarivate Analytics introduces next-gen drug R&D platform: Cortellis Drug Discovery Intelligence

MedImmune initiates first-in-human study of MEDI-5395 with durvalumab in advanced solid tumors

Terns patents new MAP3K5 inhibitors

Lycera describes MAP4K1 inhibitors

Neuropore Therapies synthesizes PI3K-AKT-mTOR pathway inhibitors

Unum shifts focus to solid tumor programs

Japanese investigators patent CRF1 and CRF2 dual receptor antagonists

Morphic Therapeutic identifies new MAdCAM antagonists

FDA clears IND for Compugen's COM-902

Halozyme Therapeutics to halt development of PEGPH20 following phase III results

FDA approves influenza vaccine Fluzone High-Dose Quadrivalent

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...